Roche’s shares tumbled nearly 5% on news that a key pillar in the five-pronged clinical plan for the breast cancer asset ...

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have made an important discovery about how genetic mutations in ...

Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge. And pharma isn’t treating it like one yet.

Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818, ...

WOMEN in the Henley area are having to travel to Reading for breast screening appointments due to parking issues at Townlands ...

Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to growth by PIK3CA mutations.

Metabolites in tissue fluid offer important clues that could help predict infection risk among women who undergo breast ...

Swiss pharma giant Novartis is to pay up to $3bn to Synnovation Therapeutics to acquire a promising breast-cancer treatment that has shown to reduce the unwanted side effects of available medicines.

persevERA is the first of two distinct Phase III studies in the first-line setting; the pionERA study of giredestrant in combination with physician’s choice of cyclin-dependent kinase (CDK)4/6 ...

A receptor involved in normal physiological processes may also drive breast cancer growth when overexpressed.

A homeowner says a housing development is causing flooding and problems with accessing garages.

Roche’s phase III persevERA Breast Cancer study of giredestrant in combo with palbociclib ER-positive advanced breast cancer fails to meet its primary objective: Basel Tuesday, ...